Results of recent trials have shown the superiority of mpMRI to TRUS-guided systematic biopsy for detecting clinically significant prostate cancer. However, only performing an mpMRI risks missing MRI-invisible lesions and, therefore, there might be added value in performing both targeted and systematic biopsies in biopsy-naive patients.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
3.0-T MR-guided transgluteal in-bore-targeted prostate biopsy under local anesthesia in patients without rectal access: a single-institute experience and review of literature
Abdominal Radiology Open Access 21 February 2024
-
Results from a PI-RADS-based MRI-directed diagnostic pathway for biopsy-naive patients in a non-university hospital
Abdominal Radiology Open Access 20 August 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Siddiqui, M. M. et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 313, 390–397 (2015).
Kasivisvanathan, V. et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N. Engl. J. Med. 378, 1767–1777 (2018).
Vourganti, S. et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J. Urol. 188, 2152–2157 (2012).
Rosenkrantz, A. B. et al. Prostate magnetic resonance imaging and magnetic resonance imaging targeted biopsy in patients with a prior negative biopsy: a consensus statement by AUA and SAR. J. Urol. 196, 1613–1618 (2016).
Calio, B. et al. Changes in prostate cancer detection rate of MRI-TRUS fusion versus systematic biopsy over time: evidence of a learning curve. Prostate Cancer Prostatic Dis. 20, 436–441 (2017).
Ahmed, H. U. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389, 815–822 (2017).
Rouviere, O. et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 20, 100–109 (2018).
Hale, G. R. et al. Comparison of elastic and rigid registration during magnetic resonance imaging/ultrasound fusion-guided prostate biopsy: a multi-operator phantom study. J. Urol. 200, 1114–1121 (2018).
Greer, M. D. et al. Computer-aided diagnosis prior to conventional interpretation of prostate mpMRI: an international multi-reader study. Eur. Radiol. 28, 4407–4417 (2018).
Mehralivand, S. et al. A magnetic resonance imaging-based prediction model for prostate biopsy risk stratification. JAMA Oncol. 4, 678–685 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The NIH and Philips have a Cooperative Research and Development Agreement. The NIH has intellectual property in the field, including among other patents and patent applications, Patent: “System, methods, and instrumentation for image guided prostate treatment” US Patent number: 8948845, with inventors/author P.A.P. The NIH and Philips (InVivo Inc) have a licensing agreement. The NIH and authors receive royalties for a licensing agreement with Philips/InVivo Inc. The NIH does not endorse or recommend any commercial products, processes or services. The views and personal opinions of the authors expressed herein do not necessarily state or reflect those of the US Government, nor reflect any official recommendation nor opinion of the NIH nor the National Cancer Institute.
Rights and permissions
About this article
Cite this article
Lebastchi, A.H., Pinto, P.A. The role of multiparametric MRI in biopsy-naive prostate cancer. Nat Rev Urol 16, 276–277 (2019). https://doi.org/10.1038/s41585-019-0173-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-019-0173-7
This article is cited by
-
3.0-T MR-guided transgluteal in-bore-targeted prostate biopsy under local anesthesia in patients without rectal access: a single-institute experience and review of literature
Abdominal Radiology (2024)
-
Results from a PI-RADS-based MRI-directed diagnostic pathway for biopsy-naive patients in a non-university hospital
Abdominal Radiology (2021)
-
Role of multiparametric prostate MRI in the management of prostate cancer
World Journal of Urology (2021)